Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 17Carboplatin 10Paclitaxel 7Trastuzumab 5Nivolumab 5Gemcitabine 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5fludarabine 4cemiplimab 4Psychiatric Rehabilitation 4Fluorouracil 4Docetaxel 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3belinostat 3Radiotherapy 3Polymerase Chain Reaction 3Methods 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Biopsy 3zimberelimab 2ulixertinib 2pertuzumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × vofatamab × Gynecologic × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡